Tango Therapeutics (TNGX) Expected to Announce Quarterly Earnings on Monday

Tango Therapeutics (NASDAQ:TNGX) is expected to release its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Tango Therapeutics to post earnings of ($0.32) per share and revenue of $0.5780 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:00 AM ET.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tango Therapeutics Price Performance

NASDAQ:TNGX traded up $1.36 during mid-day trading on Monday, reaching $22.34. The stock had a trading volume of 342,858 shares, compared to its average volume of 3,272,201. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of -25.49 and a beta of 1.22. Tango Therapeutics has a 1-year low of $1.03 and a 1-year high of $28.41. The stock’s 50 day simple moving average is $19.50 and its two-hundred day simple moving average is $13.34.

Insider Buying and Selling at Tango Therapeutics

In other Tango Therapeutics news, Director Barbara Weber sold 30,519 shares of Tango Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $374,162.94. Following the completion of the transaction, the director directly owned 1,629,254 shares in the company, valued at $19,974,654.04. The trade was a 1.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Daniella Beckman sold 10,317 shares of Tango Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $126,486.42. Following the completion of the transaction, the chief financial officer owned 184,297 shares of the company’s stock, valued at approximately $2,259,481.22. The trade was a 5.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 211,344 shares of company stock worth $3,499,842 over the last ninety days. Company insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Tango Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TNGX. Dynamic Technology Lab Private Ltd raised its holdings in Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after purchasing an additional 15,037 shares in the last quarter. Global Retirement Partners LLC bought a new stake in Tango Therapeutics during the fourth quarter worth approximately $35,000. Legal & General Group Plc raised its holdings in Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Tango Therapeutics by 44.3% during the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock worth $49,000 after purchasing an additional 2,907 shares in the last quarter. Finally, Northeast Financial Consultants Inc bought a new stake in Tango Therapeutics during the second quarter worth approximately $51,000. Institutional investors own 78.99% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on TNGX. B. Riley Financial reiterated a “buy” rating on shares of Tango Therapeutics in a research note on Friday, March 27th. Stifel Nicolaus lifted their target price on Tango Therapeutics from $24.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Canaccord Genuity Group began coverage on Tango Therapeutics in a research note on Thursday, April 2nd. They issued a “buy” rating and a $30.00 target price for the company. Wedbush lifted their target price on Tango Therapeutics from $15.00 to $19.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Finally, Wall Street Zen downgraded Tango Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Tango Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $22.44.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.